SG11201906644YA - Pparϒ agonist for the treatment of huntington's disease - Google Patents
Pparϒ agonist for the treatment of huntington's diseaseInfo
- Publication number
- SG11201906644YA SG11201906644YA SG11201906644YA SG11201906644YA SG11201906644YA SG 11201906644Y A SG11201906644Y A SG 11201906644YA SG 11201906644Y A SG11201906644Y A SG 11201906644YA SG 11201906644Y A SG11201906644Y A SG 11201906644YA SG 11201906644Y A SG11201906644Y A SG 11201906644YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- suite
- huntington
- pct
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762447741P | 2017-01-18 | 2017-01-18 | |
PCT/US2018/014240 WO2018136635A1 (en) | 2017-01-18 | 2018-01-18 | Pparϒ agonist for the treatment of huntington's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906644YA true SG11201906644YA (en) | 2019-08-27 |
Family
ID=62908392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906644YA SG11201906644YA (en) | 2017-01-18 | 2018-01-18 | Pparϒ agonist for the treatment of huntington's disease |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190350918A1 (pt) |
EP (1) | EP3570841A4 (pt) |
JP (1) | JP2020505448A (pt) |
KR (1) | KR20190122664A (pt) |
CN (1) | CN110461330A (pt) |
AU (1) | AU2018210165A1 (pt) |
BR (1) | BR112019014529A2 (pt) |
CA (1) | CA3050104A1 (pt) |
EA (1) | EA201991716A1 (pt) |
IL (1) | IL268008A (pt) |
MX (1) | MX2019008535A (pt) |
SG (1) | SG11201906644YA (pt) |
WO (1) | WO2018136635A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
EP3606527A1 (en) | 2017-04-03 | 2020-02-12 | Coherus Biosciences, Inc. | Ppar-gamma agonist for treatment of progressive supranuclear palsy |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8895541B2 (en) * | 2002-09-04 | 2014-11-25 | James A. Carnazza | Methods for inhibiting the development of huntington's disease |
US20040224995A1 (en) * | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
DE10351744A1 (de) * | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
CA2583606A1 (en) * | 2004-10-13 | 2006-04-27 | University Of Connecticut | Cannabinergic lipid ligands |
WO2009097996A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms |
WO2010040055A2 (en) * | 2008-10-03 | 2010-04-08 | Intekrin Therapeutics, Inc. | Oral pharmaceutical formulations for antidiabetic compounds |
PL2448412T3 (pl) * | 2009-07-01 | 2019-11-29 | Jds Therapeutics Llc | Kompleksy chromu jako środki podnoszące poziom transporterów glukozy w mózgu |
TW201609098A (zh) * | 2013-12-20 | 2016-03-16 | 泰瓦藥品工業有限公司 | 拉喹莫德(laquinimod)於延緩亨丁頓舞蹈症進展的用途 |
-
2018
- 2018-01-18 KR KR1020197023202A patent/KR20190122664A/ko not_active Application Discontinuation
- 2018-01-18 MX MX2019008535A patent/MX2019008535A/es unknown
- 2018-01-18 AU AU2018210165A patent/AU2018210165A1/en active Pending
- 2018-01-18 SG SG11201906644YA patent/SG11201906644YA/en unknown
- 2018-01-18 JP JP2019559015A patent/JP2020505448A/ja active Pending
- 2018-01-18 CN CN201880007571.4A patent/CN110461330A/zh active Pending
- 2018-01-18 BR BR112019014529-0A patent/BR112019014529A2/pt not_active Application Discontinuation
- 2018-01-18 EA EA201991716A patent/EA201991716A1/ru unknown
- 2018-01-18 CA CA3050104A patent/CA3050104A1/en not_active Abandoned
- 2018-01-18 WO PCT/US2018/014240 patent/WO2018136635A1/en unknown
- 2018-01-18 US US16/476,979 patent/US20190350918A1/en not_active Abandoned
- 2018-01-18 EP EP18741523.7A patent/EP3570841A4/en not_active Withdrawn
-
2019
- 2019-07-11 IL IL268008A patent/IL268008A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2019008535A (es) | 2019-12-02 |
WO2018136635A1 (en) | 2018-07-26 |
IL268008A (en) | 2019-09-26 |
EA201991716A1 (ru) | 2020-02-04 |
US20190350918A1 (en) | 2019-11-21 |
KR20190122664A (ko) | 2019-10-30 |
EP3570841A1 (en) | 2019-11-27 |
CN110461330A (zh) | 2019-11-15 |
CA3050104A1 (en) | 2018-07-26 |
EP3570841A4 (en) | 2020-08-19 |
AU2018210165A1 (en) | 2019-08-01 |
BR112019014529A2 (pt) | 2020-02-27 |
JP2020505448A (ja) | 2020-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
SG11201906373VA (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201811237WA (en) | Combination therapies | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201901320WA (en) | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
SG11201807596YA (en) | Gitr antibodies, methods, and uses | |
SG11201909837YA (en) | Methods for treating lung disorders | |
SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases |